Bayer origins examined in new ZEIT podcast probing aspirin, heroin and glyphosate
ZEIT’s new podcast series examines Bayer origins, from the invention of aspirin and early heroin products to world wars and the company’s glyphosate fallout.
ZEIT launches series tracing Bayer origins and glyphosate fallout
The weekly podcast “Der Vernichter – wie Bayer sich an Glyphosat verschluckte” opens with a detailed look at Bayer origins and the firm’s complex early products. Hosts Jens Tönnesmann and Andreas Sentker guide listeners through the company’s founding, arguing that corporate roots and scientific breakthroughs shaped a global pharmaceutical enterprise.
The series frames Bayer’s modern challenges in the context of historical decisions and inventions, promising to link past actions to present controversies. The producers position episode one as the start of a broader investigation into how a pharmaceutical pioneer became entangled with glyphosate and public scrutiny.
Episode one highlights the invention of aspirin as a turning point
Episode one centers on the invention of aspirin and its role as a commercial and scientific milestone for the fledgling company. The hosts describe how the chemical breakthrough expanded Bayer’s reach and laid the groundwork for a diversified pharmaceutical business.
Beyond the innovation itself, the podcast traces how aspirin’s success accelerated the company’s transformation from a local dye and chemicals concern into an international brand. The narrative underscores aspirin as both a medical breakthrough and a catalyst for rapid corporate growth.
Early product lines included heroin and shaped Bayer’s reputation
Tönnesmann and Sentker examine lesser-known early products, noting that heroin was marketed by the company in its formative years. The podcast places these products in historical context, explaining contemporary medical thinking and commercial incentives that informed such developments.
The account does not shy away from the reputational consequences of those choices, arguing that early product lines continue to influence public perceptions of Bayer today. By revisiting these decisions, the hosts intend to show how past commercial strategies echo in present controversies.
Wartime expansion and sport-linked networks influenced growth
The series explores how the two world wars affected Bayer’s trajectory, altering production priorities and corporate organization. Episode one traces wartime expansions and contractions and shows how geopolitical forces reshaped the company’s markets and personnel.
Unexpected social threads, including the role of football and other communal networks, are used to illustrate how business relationships and cultural institutions aided Bayer’s domestic consolidation. The hosts use these angles to demonstrate that corporate evolution is shaped by a mix of science, politics and community ties.
Production details and how to access the podcast
All episodes are available exclusively to listeners with a podcast or digital subscription from DIE ZEIT, with both subscription types offering a one-month free trial for new users. The production credits list Pool Artists as the production company and Joscha Grunewald for sound design, underscoring a polished, narrative-driven format.
Jens Tönnesmann and Andreas Sentker are credited for moderation and research, while Constanze Kainz and Ole Pflüger served as project leaders for the series. These production details signal a newsroom-style investigation designed for listeners who seek in-depth historical and corporate analysis.
Series frames Bayer’s past as context for contemporary disputes
The podcast explicitly connects Bayer origins to later controversies, most notably the ongoing debates around glyphosate and corporate accountability. By placing modern disputes alongside historical episodes, the series aims to provide listeners with context for understanding regulatory, legal and reputational challenges facing the company.
This approach suggests the producers want to move beyond headline-driven coverage and toward a structural reading of how scientific innovation, market forces and policy decisions interact over time. Listeners are invited to evaluate how earlier choices persisted into the present day.
DIE ZEIT’s new series begins as a historical inquiry with clear contemporary relevance, mapping a path from 19th-century chemical manufacturing through the globalisation of pharmaceuticals and into the debates that shape Bayer’s public image today.
